In order to overcome the acquired resistance, next-generation EGFR TKIs have been approved for NSCLC therapy, and several promising candidates are currently undergoing clinical trials [14,15,16,17,18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.